Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaproxgression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway

Qi Wei1,*, Yuan Ren1,*, Xia Zheng2,*, Sufang Yang1, Tongting Lu1, Hongyao Ji3, Haiqing Hua4, and Kuizhong Shan4

*Department of Oncology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Yancheng, China; 4Department of Oncology, The Second People’s Hospital of Kunshan, Suzhou, China; 2Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Shanghai, China; 4Department of Oncology, NanJing JinLing Hospital, Nanjing, China

ABSTRACT

Hepatocellular carcinoma (HCC) is the most common pathological type of primary hepatic carcinoma. This study investigated the effects of ginsenoside Rg3 (Rg3) and sorafenib (SFN) combination therapy on HCC progression. The HCC-related data were obtained from TCGA database, and the data of HK2 mRNA, clinicopathological features, and survival outcomes were extracted using R Programming 4.0. The human hepatoma cell lines HepG2 and Bel7404 were used. Cell viability was tested using the MTT assay. Glucose consumption and lactate levels of HCC cells were detected using the corresponding kits. Western blotting was used to determine the protein expression of HK2, PI3K, and Akt. HK2 was overexpressed in patients with HCC. Compared with patients with overexpressed HK2, those with low levels of HK2 achieved a longer survival time. In addition, the Rg3 and SFN combination therapy significantly reduced cell viability, glucose consumption, lactate levels, and protein expression of HK2, PI3K, and Akt in HCC cells. Additionally, the Rg3 and SFN combination therapy exhibited a better effect than the single drug group. Inhibition of the PI3K/Akt signaling pathway or exogenous lactate intervention reversed the effects of Rg3 and SFN combination therapy in HCC cells. In conclusion, Rg3 has a synergistic effect on the sensitivity of HepG2 and Bel7404 hepatoma cells to SFN, which is related to HK2-mediated glycolysis and the PI3K/Akt signaling pathway.

Highlights

1. Rg3 combined with SFN inhibited cell viability of the HCC cells
2. HK2 was up-regulated in the HCC patient
3. Rg3 combined with SFN suppressed the PI3K/Akt signaling pathway

Introduction

Primary hepatic carcinoma (PHC) is a common clinically malignant tumor. Hepatocellular carcinoma (HCC) accounts for 90% of all PHC cases and is the most common pathological type [1]. According to the latest statistics, in 2020, there were 906,000 new liver cancer cases and 83,000 deaths worldwide, accounting for 8.3% of all cancer-related deaths, ranking third [2].

Currently, the treatment methods for HCC mainly include surgical resection, interventional therapy, chemotherapy, targeted therapy, and immunotherapy [3]. Based on the results of previous studies, since the end of 2007, the Food and Drug Administration of the USA and China have approved the use of sorafenib (SFN) as the first-line treatment for advanced HCC [4,5]. SFN was the first drug to achieve success in the systematic treatment of HCC, and significantly delays disease progression and prolongs overall survival (OS) [6]. However, SFN treatment exhibits a low median OS and objective response rate, which are usually accompanied by several side effects and drug resistance [7]. Hence, the efficacy of SFN does not meet the current treatment requirements for HCC.

CONTACT Haiqing Hua hua_haiqing1234@163.com Department of Oncology, NanJing JinLing Hospital, Nanjing 210000, China; Kuizhong Shan zhong85@163.com Department of Oncology, The Second People’s Hospital of Kunshan, Suzhou 215300, China

*These authors contributed equally to this article.

Supplemental data for this article can be accessed online at https://doi.org/10.1080/21655979.2022.2074616

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In view of the limitations of single-drug treatment, various combined treatment schemes have been used and have shown satisfactory results in the first-line treatment of advanced liver cancer [8,9]. Studies have found that traditional Chinese medicine has excellent antitumor effects and can enhance immune function [10]. Ginsenoside Rg3 (Rg3) is a terpenoid and an active component of ginseng, which can affect multiple metabolic pathways and play a variety of roles in the body, such as repairing damage and anti-tumor and anti-oxidation effects [11–13]. Recently, several studies have confirmed that Rg3 effectively inhibits HCC progression [14,15]. However, the role of Rg3 and SFN combination therapy in HCC remains unclear.

Therefore, this study investigated the effects of Rg3 and SFN combination therapy on the progression of HCC. This was the first time to explore their role in glycolysis. We hypothesized that Rg3 and SFN combination therapy might relieve HCC progression by regulating glycolysis and inhibiting the PI3K/Akt signaling pathway.

Material and methods

Bioinformatic analysis

The relevant data from TCGA LIHC cohort (Liver Cancer) in TCGA database (https://portal.gdc.cancer.gov/) were downloaded using ggpubr analysis in R language. A total of 377 patients with HCC were included, of which 371 were analyzed for the mRNA levels of HK2 in HCC tissues and were matched with the mRNA levels of HK2 in 50 normal liver tissues. The patient clinical information was also obtained.

Cell culture and treatment

Human hepatoma cell lines (HepG2 and Bel7404) were used in this study. Both cell lines were purchased from the cell bank of the Chinese Academy of Science (Shanghai, China) and cultured in DMEM (Sbjbio, Nanjing, China) containing 10% FBS (Sbjbio) and 1% (penicillin + streptomycin) at 37°C and 5% CO₂. The cells were then divided into six groups: NC (control), SFN (5 µM SFN) [16], Rg3 (130 µM Rg3) [17], SFN+Rg3, SFN+Rg3 + 740Y-P (20 ug/ml 740Y-P), and SFN+Rg3+ lactate (culture environment adjusted to pH 6.8 with lactate). Rg3 was purchased from Chengdu Mansite Biotechnology Co., Ltd. (Chengdu, China). SFN was provided by our hospital.

MTT assay

Logarithmic phase cells were routinely digested and inoculated into 96 well plates (5 × 10⁴ cells/well) [18]. The cells were incubated under standard conditions for 24 h. Next, 20 µL of MTT was added in the dark, and the cells were incubated with MTT for 4 h. Finally, the absorbance was measured at 490 nm using a microplate reader. The experiments were conducted in triplicate.

Determination of glucose consumption

Glucose consumption was measured using a glucose consumption assay kit (Abcam, USA) [19]. Briefly, cells were inoculated into 96 well plates. After culturing in sugar-free medium for 1 h, cells were incubated with 100 µmol/L 2-NBDG at 37°C for 1 h. Finally, fluorescence was detected using a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The experiments were conducted in triplicate.

Determination of lactate (lactate) content

The lactate content was detected using a lactate assay kit (Jiancheng, Nanjing, China) [20]. Briefly, cells were seeded in 96 well plates. According to the manufacturer’s instructions, 50 µL of the culture medium was added to each well, and three wells were set in each group. The enzyme working solution and chromogenic agent were then added to each well. After mixing in a vortex mixer, the cells were cultured at 37°C for 10 min. A terminator was then added to stop the reaction. Finally, an enzyme labeling instrument was used to detect the absorbance at 570 nm.
Western blotting assay

Protein was extracted with RIPA lysis buffer and measured with a BCA Protein Quantification Kit (Jiancheng, Nanjing, China). SDS-PAGE (10%) was used to separate the protein (40 μg), which was then transferred onto PVDF membranes. The membranes were then treated with nonfat milk powder for 1 h and incubated with anti-HK2 (1:800; Abcam, USA), anti-p-PI3K (1:1000; Abcam), anti-PI3K (1:1200, Abcam), anti-p-AKT (1:800, Abcam), anti-AKT (1:900, Abcam), and anti-GAPDH (1:2500, Abcam) for 12 h. The membranes were then incubated with the secondary antibodies (1:1000; Abcam, USA) for 2 h. Finally, the protein bands were visualized using an ECL system (Thermo Fisher Scientific, Inc.) with GAPDH as the internal parameter [21].

Statistical analysis

The data in the current study were analyzed using SPSS 20.0, and are expressed as mean ± SD. The mRNA levels of HK2 in the 377 HCC patients were analyzed using a receiver operating characteristic (ROC) curve to determine its sensitivity, specificity, and cutoff value for predicting patient survival. The χ² test method was used to analyze the relationship between HK2 expression level and the clinical and pathological information of the patient. The Kaplan-Meier method was used to draw the OS curve and the Log-Rank method was used to test the survival difference between the two groups. The COX Regression analysis model was used for multi-factor analysis. Statistical significance was set at P < 0.05.

Results

This study demonstrated that Rg3 combined with SFN effectively depleted the cell viability, glucose consumption, and lactate levels of HCC cells. Mechanistically, inhibition of the PI3K/AKT signaling pathway may be the key to HCC treatment.

Clinical characteristics

A total of 371 patients were divided into high level HK2 group (n = 255) and low level HK2 group (n = 116). Compared with patients with low levels of HK2, patients with high levels of HK2 showed more T stages from T3 to T4 (21.6% vs. 32.8%, P = 0.028), higher lymph node metastasis rate (28.6% vs. 39.7%, P = 0.041), lower hepatitis virus infection rate (26.7% vs. 47.8%, P = 0.00), and a higher probability of AFP > 400 ng/ml (17.3% vs. 18.1%, P = 0.00). Sex, age, race, family history, histological grade, and distant metastasis were not significantly different between the two groups (Table 1).

Univariate and multivariate regression analysis of survival in patients with HCC

The COX regression analysis showed that HCC patients aged ≥ 61 years (HR = 1.027, 95% CI: 1.009–1.045), non-Asians (HR = 2.042, 95% CI: 1.264–3.298), family history (HR = 1.795, 95% CI: 1.160–2.778), T3- T4 stage (HR = 1.806, 95% CI: 1.011–3.246), and metastasis (HR = 2.085, 95% CI: 1.224–3.562) were independent risk factors for OS. The risk of recurrence increased with age (P < 0.001), stage (P < 0.001), and metastasis (P = 0.002).
1.132–2.882), lymph node invasion (HR = 1.959, 95% CI: 1.274–3.014), and distant metastasis (HR = 2.452, 95% CI: 1.600–3.759) had a higher risk of death, whereas those with viral infection (HR = 0.567, 95% CI: 0.363–0.884) had a lower risk of death. The expression of HK2 also predicted an increased risk of death (HR = 1.566, 95% CI: 1.000–2.452). Additional multivariate regression analysis found that high expression of HK2 (HR = 1.893, 95% CI: 1.164–3.079), age ≥ 61 years (HR = 1.026, 95% CI: 1.005–1.047), and distant metastasis (HR = 2.298, 95% CI: 1.253–4.215) were independent predictors of increased mortality in HCC patients (Table 2).

**Rg3 combined with SFN declined cell viability of the HCC cells**

The Rg3 molecular structure formula is displayed in Figure 1(a). The viability of HCC cells in the Rg3 (inhibitory rate: 27.518 ± 5.031% in HepG2; 9.927 ± 2.743% in Bel7404) and SFN (inhibitory rate: 33.020 ± 2.641% in HepG2;16.974 ± 3.229% in Bel7404) groups was found to be prominently depleted. In addition, the cell viability of the two combination therapy groups (inhibitory rate: 60.135 ± 1.982% in HepG2; 56.082 ± 2.934% in Bel7404) was lower than that of the single drug groups. Furthermore, after the intervention of the PI3K/Akt signaling pathway agonist 740Y-P and lactate, the therapeutic effects of Rg3 and SFN were neutralized (Figure 1(b, c)).

**HK2 was up-regulated in the HCC patient**

The mRNA levels of HK2 in the 371 HCC tissues and 50 normal liver tissues were obtained from TCGA database. Compared to normal tissues, HK2 mRNA repression was upregulated in HCC tissues (Figure 2(a)). The ROC curves showed that patients with HCC achieved an AUC of 0.59 (95% CI 0.53–0.65). Sensitivity and specificity were 39.2% and 78.3%, respectively (Figure 2(b)). According to the ROC curves, the cutoff value for HK2 mRNA was 273. According to TCGA cohorts, compared with patients in the high expression group, patients in the HK2 low expression group survived longer (mOS = 70.53 vs. 42.37 months, P = 0.048) (Figure 2(c)). The Kaplan-Meier plots revealed that patients with HCC with high HK2 expression had a shorter survival time. These findings were consistent with the results of TCGA database analysis (Figure 2(d)).

**Table 2.** Univariate and multivariate regression analysis were used to evaluate survival related factors.

|                      | Univariate Analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | HR (95% CI)         | P                     | HR (95% CI)         | P             |
| Gender (female vs male) | 0.758 (0.498–1.154) | 0.196                 | 1.026 (1.005–1.047) | 0.015         |
| Age (>61 vs ≤61)  | 1.027 (1.009–1.045) | 0.003                 | 1.297 (0.665–2.532) | 0.445         |
| Race (Non Asian vs Asian) | 2.042 (1.264–3.298) | 0.004                 | 1.403 (0.882–2.232) | 0.153         |
| Family History (Yes vs No) | 1.795 (1.160–2.778) | 0.009                 | 1.585 (0.959–2.617) | 0.072         |
| Histological Grading (G1 vs G2) | 0.955 (0.609–1.495) | 0.839                 | 1.585 (0.959–2.617) | 0.072         |
| T Stage (T1 vs T2 vs T3) | 1.806(1.132–2.882) | 0.013                 | 1.585 (0.959–2.617) | 0.072         |
| Lymph Node Metastasis (N0 vs N+) | 1.959(1.274–3.014) | 0.002                 | 1.585 (0.959–2.617) | 0.072         |
| Distant Metastasis (M1 vs M0) | 2.452(1.600–3.759) | 0.000                 | 1.585 (0.959–2.617) | 0.072         |
| Virus Infection (Yes vs No) | 0.567(0.363–0.884) | 0.012                 | 1.318 (0.735–2.365) | 0.354         |
| AFP (<400 ng/ml vs >400 ng/ml) | 0.918(0.524–1.607) | 0.764                 | 1.318 (0.735–2.365) | 0.354         |
| HK2 mRNA level (>273 vs ≤273) | 1.566(1.000–2.452) | 0.050                 | 1.893 (1.164–3.079) | 0.010         |

**Rg3 combined with SFN declined the glucose consumption and lactate levels of the HCC cells**

Subsequently, we analyzed glucose consumption and lactate levels in the HCC cells. Both Rg3 and SFN prominently reduced glucose consumption (Figure 2(a, b)) and lactate levels (Figure 2(c, d)) in HCC cells. Moreover, glucose consumption and lactate levels in the two combination therapy groups were lower than those in the single drug groups. Additionally, after the intervention of the PI3K/Akt signaling pathway agonist 740Y-P and lactate, the effects of Rg3 and SFN on glucose consumption and lactate levels were neutralized.
Finally, as shown in Figure 4, we found that both Rg3 and SFN prominently reduced HK2, p-PI3K, and p-AKT protein expression in HCC cells. In addition, HK2, p-PI3K, and p-AKT protein expression levels in the two combination therapy groups were lower than those in the single drug groups. Furthermore, after the intervention of the PI3K/Akt signaling pathway agonist 740Y-P and lactate, the effects of Rg3 and SFN on HK2, p-PI3K, and p-AKT protein expressions were neutralized.

**Discussion**

We demonstrate that Rg3 combined with SFN effectively depleted the cell viability, glucose consumption, and lactate levels of HCC cells. Mechanistically, inhibition of the PI3K/AKT signaling pathway may be the key to HCC treatment.

PHC has a high incidence in China, with HCC being the most common pathological type [22]. The prevalence of the hepatitis B virus has increased the incidence of HCC in China [23]. SFN, a safe and effective drug, has achieved success in the systematic treatment of HCC [24]. SFN can significantly delay...
Figure 2. Rg3 combined with SFN declined the glucose consumption and lactate levels of the HCC cells. (a-b) the glucose consumption of the HCC cells. (c-d) THE lactate levels of the HCC cells. *P < 0.05, **P < 0.01 VS NC group. #P < 0.05 VS SFN or Rg3 group. &P < 0.05 VS SFN+ Rg3 group.

disease progression and improve OS. However, the OS of SFN for Asian patients is only 6.5 months and the objective response rate is only 3%, and is accompanied by several side effects and drug resistance [25]. The anti-tumor effect of traditional Chinese medicine is mild and can enhance immune function [10]. Several studies have shown that ginsenoside is almost nontoxic to normal human cells and has anti-tumor effects, reduces the toxicity of radiotherapy and chemotherapy, and improves immunity [26,27]. Several types of ginsenosides have been identified. Among these, Rg3 exhibits the best anticancer effect [11]. Many studies have demonstrated that Rg3 suppresses the growth of various cancers, such as breast [28], lung [29], and ovarian cancers [17]. As the overall anti-cancer effect of traditional Chinese medicine is weak, it is difficult to control the development of tumors when used alone, and the combination of radiotherapy and chemotherapy has a detoxification and synergistic effect [30,31]. Accumulating evidence has confirmed that Rg3 combined with SFN has a synergistic effect in inhibiting tumor cell growth [32,33]. In this study, we confirmed that Rg3 combined with SFN inhibited cell viability more effectively than Rg3 or SFN alone.

Glycolysis is a basic characteristic of malignant tumors [34]. The Warburg effect is involved in regulating various biological behaviors of malignant tumors, including transitional proliferation, blocked apoptosis, drug resistance, immune escape, and angiogenesis [35,36]. It has been found that the application of glycolysis inhibitors can reverse the drug resistance of liver cancer cells and enhance their sensitivity to SFN [37]. HK2, a key metabolic enzyme, can promote the Warburg effect and tumor growth [38]. HK2 has been reported to be related to the occurrence and migration of a variety of malignant tumors and regulate physiological processes [39,40]. In this study, we confirmed that Rg3 combined with SFN reduced the glucose consumption and lactate levels in HCC cells. In addition, according to the data analysis of TCGA database, patients with high expression of HK2 had shorter survival times.
Figure 3. HK2 was up-regulated in the HCC patient. (a) the HK2 mRNA levels of the HCC patients. (b) ROC curve analysis of HCC patients. (c-d) TCGA cohort and Kaplan-Meier Plotter analysis was used to draw the overall survival curve.
These results suggest that glycolysis is involved in SFN resistance, and that inhibition of glycolysis can enhance the sensitivity of drug-resistant cell lines to SFN.

The PI3K/Akt signaling pathway is recognized as the first pathway for cancer cell survival [41]. Several studies have shown that the PI3K/Akt pathway is over-activated in malignant tumors and affects the malignant behavior of cancer cells [42]. Recent studies have shown that inhibiting the activation of the PI3K/Akt signaling pathway suppresses the proliferation of hepatoma cells.

Additionally, the sensitivity of hepatoma cells to SFN is enhanced by activating this pathway [43,44]. PI3K belongs to the proto-oncogene family, and Akt occupies a pivotal position in this pathway. p-Akt is the activated form of Akt, which can affect many target proteins downstream of the pathway through phosphorylation [45]. Therefore, the levels of p-PI3K and p-Akt directly reflect the activity of this pathway. Our study demonstrated that Rg3 combined with SFN treatment reduced p-PI3K and p-Akt protein levels. We also observed that inhibition of the PI3K/Akt signaling pathway

Figure 4. Rg3 combined with SFN suppressed the PI3K/Akt signaling pathway and HK2 levels. (a-h) the protein expressions of HK2, PI3K, Akt of the HCC cells were detected by western blots. *P < 0.05, **P < 0.01 VS NC group. #P < 0.05, ##P < 0.01, VS SFN or Rg3 group. &P < 0.05, &&P < 0.01 VS SFN+ Rg3 group.
neutralized the effects of Rg3 combined with SFN treatment in HCC cells. These results imply that inhibition of the PI3K/Akt signaling pathway is key to the treatment of HCC.

Conclusion

In summary, this study demonstrated that Rg3 and SFN combination therapy effectively relieved HCC progression by regulating glycolysis and inhibiting the PI3K/Akt signaling pathway.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported current work was supported by funds from Kunshan key R & D plan (NO. KS.1905)

ORCID

Haiqing Hua @ http://orcid.org/0000-0002-2033-0467

References

[1] Ranganathan S, Lopez-Terrada D, Alaggio R. Hepato blastoma and pediatric hepatocellular carcinoma: an update. Pediatr Dev Pathol. 2020;23(2):79–95.
[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
[3] Ikeda M, Morizane C, Ueno M, et al. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48(2):103–114.
[4] Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9(6):739–745.
[5] Cheng AD, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
[6] Xia S, Pan Y, Liang Y, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610.
[7] He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960.
[8] Li Z, Jiao D, Han X, et al. Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma. Cancer Imaging. 2020;20(1):13.
[9] Feng J, Yang, JH, Li, JH, et al. Transcatheter arterial chemoembolisation combined with radiofrequency ablation on hepatocellular carcinoma and levels of relevant markers. J Coll Physicians Surg Pak. 2020;30(3):259–262.
[10] Wang Y, Zhang Q, Chen Y, et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother. 2020;121:109570.
[11] Sun M, Ye Y, Xiao L, et al. Anticancer effects of ginsenoside Rg3 (Review). Int J Mol Med. 2017;39(3):507–518.
[12] Li L, Wang Y, Guo R, et al. Ginsenoside Rg3-loaded, reactive oxygen species-responsive polymeric nanoparticles for alleviating myocardial ischemia-reperfusion injury. J Control Release. 2020;317:259–272.
[13] Lee H, Kong G, Tran Q, et al. Relationship between ginsenoside Rg3 and metabolic syndrome. Front Pharmacol. 2020;11:130.
[14] Ren Z, Chen X, Hong L, et al. Nanoparticle conjugation of ginsenoside Rg3 inhibits hepatocellular carcinoma development and metastasis. Small. 2020;16(2):e1905233.
[15] Hu S, Zhu Y, Xia X, et al. Ginsenoside Rg3 prolongs survival of the orthotopic hepatocellular carcinoma model by inducing apoptosis and inhibiting angiogenesis. Anal Cell Pathol (Amst). 2019;2019:3815786.
[16] Wu CX, Wang XQ, Chok SH, et al. Blocking CDK1/ PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018;8(14):3737–3750.
[17] Zhao L, Shou H, Chen L, et al. Effects of ginsenoside Rg3 on epigenetic modification in ovarian cancer cells. Oncol Rep. 2019;41(6):3209–3218.
[18] Lu X, Gao H, Zhu B, et al. Circular RNA circ_RANBP9 exacerbates polycystic ovary syndrome via microRNA -136-5p/XIAP axis. Bioengineered. 2021;12(1):6748–6758.
[19] Perez-Rodriguez S, Ramirez-Lira MDJ, Trujillo-Roldán MA, et al. Nutrient supplementation strategy improves cell concentration and longevity, monoclonal antibody production and lactate metabolism of Chinese hamster ovary cells. Bioengineered. 2020;11(1):463–471.
[20] Li H, Xuan J, Zhang W, et al. Long non-coding RNA SNHG5 regulates ulcerative colitis via microRNA-375/ Janus kinase-2 axis. Bioengineered. 2021;12(1):4150–4158.
[21] Han D, Yu Z, Zhang H, et al. Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RTqPCR, Western blotting, and immunohistochemistry. Bioengineered. 2021;12(2):10891–10904.
[22] Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging
diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 2015;44(6):479–486.

[23] Jianhuang, Huang J, Deng Q, et al. Exome sequencing of hepatitis B virus—associated hepatocellular carcinoma. Nat Genet. 2012;44(10):1117–1121.

[24] Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.

[25] Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.

[26] Zheng Q, Bao X-Y, Zhu P-C, et al. Ginsenoside Rh1 for myocardial ischemia/reperfusion injury: preclinical evidence and possible mechanisms. Oxid Med Cell Longev. 2017;2017:6313625.

[27] Liu T, Luo D, Duan P. Ginsenoside Rg3 sensitizes colorectal cancer to radiotherapy through downregulation of proliferative and angiogenic biomarkers. Evid Based Complement Alternat Med. 2018;2018:1580427.

[28] Nakhjavani M, Hardingham, JE, Palethorpe, HM, et al. Ginsenoside Rg3: potential molecular targets and therapeutic indication in metastatic Breast cancer. Medicines (Basel). 2019;6(1):17.

[29] Dai Y, Wang W, Sun Q, et al. Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines. Exp Ther Med. 2019;17(1):953–959.

[30] Qi F, Zhao L, Zhou A, et al. The advantages of using traditional Chinese medicine as an adjuvant therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015;9(1):16–34.

[31] Xue JX, Zhu Z-Y, Bian W-H, et al. The traditional Chinese medicine kàngjì injection as an adjuvant method in combination with chemotherapy for the treatment of breast cancer in Chinese patients: a meta-analysis. Evid Based Complement Alternat Med. 2018;2018:6305645.

[32] Lu M, Fei Z, Zhang G. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. Biomed Pharmacother. 2018;97:1282–1288.

[33] Kim DG, Jung KH, Lee D-G, et al. 20(S)-ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget. 2014;5(12):4438–4451.

[34] Yang J, Ren B, Yang G, et al. The enhancement of glycolysis regulates pancreatic cancer metastasis. Cell Mol Life Sci. 2019;77(2):305–321.

[35] Vaupel P, Multhoff G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol. 2021;599(6):1745–1757.

[36] Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;356 (2 Pt A):156–164.

[37] Zhang Z, Tan X, Luo J, et al. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis. 2020;11(10):902.

[38] Wang Q, Guo X, Li L, et al. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020;11(10):911.

[39] Garcia SN, Guedes RC, Marques MM. Unlocking the potential of HK2 in cancer metabolism and therapeutics. Curr Med Chem. 2019;26(41):7285–7322.

[40] Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308.

[41] Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797.

[42] Edirweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–160.

[43] Bamodu OA, Chang H-L, Ong J-R, et al. Elevated PDK1 expression drives PI3K/AKT/MTOR signaling promotes radiation-resistant and dedifferentiated phenotype of hepatocellular carcinoma. Cells. 2020;9(3):746.

[44] Sun F, Wang, J, Sun Q, Q, et al. Interleukin-8 promotes integrin beta3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):449.

[45] Jafari M, Ghadami, E, Dadkiah, T, et al. PI3k/AKT signaling pathway: erythropoiesis and beyond. J Cell Physiol. 2019;234(3):2373–2385.